Kairos Pharma Financials - Benzinga

Kairos Pharma Ltd

KAPAAMEX

Trade with Public

Trade with Public

$0.3410

-0.019-5.28%

At close: Aug 14, 5:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Kairos Pharma Financials

Kairos Pharma (KAPA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same

Benzinga Newsdesk

PRO
Kairos Pharma Q2 EPS $(0.08) Misses $(0.05) Estimate

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent.

Benzinga Newsdesk

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Avi Kapoor

PRO
Kairos Pharma Q1 EPS $(0.08) Misses $(0.05) Estimate

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent.

Benzinga Newsdesk

PRO
Kairos Pharma Outlines Key 2024 Milestones; Highlights IPO On NYSE, $3.5M PIPE Transaction, Phase 2 Trials For ENV105 Cancer Therapies; Anticipates 2025 Safety Data And Partnering Talks

Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview of key 2024 milestones and outlook

Benzinga Newsdesk